GERALD KIDD: Open Payments
NPI 1265552210 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,391 in 111 payments from 19 companies in 2025. Trend: 2023 $1,557 · 2024 $1,753 · 2025 $2,391
Food & beverage: $2,391
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $244 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $230 |
| Gilead Sciences, Inc. | 10 | $195 |
| Janssen Biotech, Inc. | 8 | $187 |
| QOL Medical, LLC | 9 | $154 |
| GENZYME CORPORATION | 6 | $140 |
| Ardelyx, Inc. | 4 | $131 |
| Regeneron Healthcare Solutions, Inc. | 5 | $108 |
| Madrigal Pharmaceuticals | 4 | $86 |
Products named: RINVOQ, DUPIXENT, XIFAXAN, ENTYVIO, TREMFYA, Sucraid, IBSRELA, SKYRIZI.
Industry payments across CO — which companies pay providers there.
